Phase III data suggests long-acting cabotegravir injection more effective than daily oral Truvada (emtricitabine/tenofovir) for HIV pre-exposure prophylaxis in women

In the Phase III trial in HIV-ve women in Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda and Zimbabwe, the HIV incidence rate was 0.21% (95% CI 0.06%-0.54%) in the cabotegravir group and 1.79% (1.24%-2.51%) in the Truvada group. The blinded phase has now been stopped.

Source:

British Medical Journal